Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

March 26, 2019 5:00 pm

IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 22, 2019 5:00 pm

By Christina Bennett, MS

Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer

March 17, 2019 6:00 pm

By Ian Ingram

In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

Compared with placebo, … Read more

SGO 2019: Dendritic Cell-Based Immunotherapy Appears Promising for Recurrent Ovarian Cancer

March 16, 2019 5:00 pm

The treatment offers long-lasting anti-tumor immunity.

The addition of a dendritic cell immunotherapy to chemotherapy has been found to prolong overall survival significantly in patients with recurrent ovarian cancer. The combination of chemotherapy + immunotherapy corresponded to 73% survival after … Read more

Tackling Cancer Anxiety

November 18, 2018 6:29 pm

By Susan Gubar

No matter how long I deal with periodic blood tests, abdominal CTs and mammograms, they always trigger a huge wave of ‘scanxiety.’

Last year, right before the winter holidays, the nurse practitioner palpating my breast paused and … Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

To Test or Not To Test: A Thorny Question in Ovarian Cancer Maintenance

September 19, 2018 9:28 pm

BY Kelly Irvin

I’ve officially entered the twilight zone. No, not the one Rod Serling spoke of on that classic TV show. This is that murky, dark period when the tumor markers associated with ovarian cancer start creeping up. While … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more

Quality of Life Maintained With Niraparib for Ovarian Cancer

August 1, 2018 9:19 pm

by Madeline Marr

The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.

An international team of researchers led … Read more

Triggering an Immune Response in Ovarian Cancer

July 17, 2018 2:04 am
by Mark L. Fuerst

A novel personalized vaccine made from an ovarian cancer patient’s tumor tissue and immune cells was found in early research to stimulate potent therapeutic immune responses, extending overall survival for patients with recurrent disease.

The vaccine,

Read more

Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?

June 19, 2018 5:43 pm

A new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more

Clearity Presents Results at ASCO Conference

June 13, 2018 7:22 pm

Results from analysis of clinical and tumor profiling data from ovarian cancer patients in the Clearity Foundation Data Repository were presented in two studies at the recent ASCO conference that took place June 1-5 in Chicago, Ill.

The first study

Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

Pembrolizumab Monotherapy Shows Activity in Advanced Recurrent OC

June 7, 2018 9:52 pm

Pembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2 KEYNOTE-100 study suggest.

Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer

May 29, 2018 7:07 pm

Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response. Writing in Clinical Cancer Research, investigators at the Mayo Clinic report that … Read more

New Immunotherapy Shows Promise Against Ovarian Cancer

April 10, 2018 8:57 pm

Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.

One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more